Journal of ethnopharmacology · 2026
Citri Grandis Exocarpium with medicine and food homology: A review regarding its potential anti-obesity effects and future applications.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Peng-Fei, Du Yuan-Yun, Zheng Shao-Long, Qian Zheng-Ming, Zhou Jin-Lin, Huang Zhi-Shu, Hu Yuan-Jia
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Citri Grandis Exocarpium (CGE), a traditional Chinese medicinal herb with a long history of medicine and food homology, has been documented in Gleanings from the Materia Medica for its efficacy. Modern research has revealed that the active components exhibit anti-inflammatory properties and metabolic regulatory functions, emerging as a promising candidate for the treatment of obesity.
AIM OF THE REVIEW: This review aims to conduct a comprehensive analysis of the pharmacological material, mechanisms, and clinical translational prospects underlying the anti-obesity effect of CGE. It also proposes to evaluate its potential utility as a medicine and food homology in obesity prevention and treatment, and address its limitations, and propose solutions for existing research in this field.
METHODS: This review primarily focused on elucidating the mechanism and effectiveness of CGE in treating obesity and its related complications, by searching across electronic databases, including PubMed, Web of Science, Scopus, Google Scholar, and CNKI.
RESULTS: The effective phytochemicals, molecular mechanisms, and product applications of CGE in the prevention and treatment of obesity and related complications were summarized. Specifically, naringin, limonene, and other key components are crucial in activating the AMPK signaling pathway to inhibit lipid accumulation, and regulating the gut microbiota to improve metabolic inflammation. In addition, CGE exerts regulatory effects on lipogenesis and energy metabolism by influencing crucial genes such as Ucp1 and Pgc-1α, positioning CGE as a potential therapeutic drug and healthy food for addressing obesity and its associated metabolic disorders.
CONCLUSION: Owing to the synergistic effect of its diverse bioactive constitutes as well as its medicinal-food application properties, CGE has become a promising candidate for anti-obesity interventions. However, existing studies have certain limitations that have not been widely and deeply investigated. In the future, more rigorous clinical trials, innovative delivery technologies, and internationally recognized standards are required to support the transition of CGE from traditional empirical practice to an evidence-based therapeutic option.
AIM OF THE REVIEW: This review aims to conduct a comprehensive analysis of the pharmacological material, mechanisms, and clinical translational prospects underlying the anti-obesity effect of CGE. It also proposes to evaluate its potential utility as a medicine and food homology in obesity prevention and treatment, and address its limitations, and propose solutions for existing research in this field.
METHODS: This review primarily focused on elucidating the mechanism and effectiveness of CGE in treating obesity and its related complications, by searching across electronic databases, including PubMed, Web of Science, Scopus, Google Scholar, and CNKI.
RESULTS: The effective phytochemicals, molecular mechanisms, and product applications of CGE in the prevention and treatment of obesity and related complications were summarized. Specifically, naringin, limonene, and other key components are crucial in activating the AMPK signaling pathway to inhibit lipid accumulation, and regulating the gut microbiota to improve metabolic inflammation. In addition, CGE exerts regulatory effects on lipogenesis and energy metabolism by influencing crucial genes such as Ucp1 and Pgc-1α, positioning CGE as a potential therapeutic drug and healthy food for addressing obesity and its associated metabolic disorders.
CONCLUSION: Owing to the synergistic effect of its diverse bioactive constitutes as well as its medicinal-food application properties, CGE has become a promising candidate for anti-obesity interventions. However, existing studies have certain limitations that have not been widely and deeply investigated. In the future, more rigorous clinical trials, innovative delivery technologies, and internationally recognized standards are required to support the transition of CGE from traditional empirical practice to an evidence-based therapeutic option.